Tosoh Bioscience is a global leader in the field of liquid chromatography with a focus on bioseparations. Tosoh Bioscience is providing cutting-edge solutions to meet the needs of customers developing and producing new biologics, biosimilars or biobetters, such as plasma products, monoclonal antibodies, recombinant proteins, vaccines and oligonucleotides.
Our product portfolio encompasses SEC instruments and a comprehensive line of media and prepacked process development, HPLC, and UHPLC columns. These products are popular in the biotech and biopharmaceutical industry and used in R&D, downstream processing, and quality control. Typical applications comprise the purification of therapeutic proteins in lab, pilot, and commercial scale, as well as their characterization by U/HPLC.
The Octave BIO Multi-Column Chromatography (MCC) system is the first in a series of MCC instruments targeting all stages of biomolecule manufacturing, from preclinical to clinical and GMP manufacturing. The bioseparation product line is supplemented by the LenS3 MALS detector and EcoSEC GPC/SEC instruments with matching GPC columns for the characterization of natural and synthetic polymers.
Headquartered in Griesheim, Germany, Tosoh Bioscience‘s European operations offer technical support like application development, on-site training and workshops. One of the services that stand out in the industry is the Tosoh Chromatography Workshop Series providing a comprehensive background to the purification of biomolecules. Tosoh Bioscience is part of the Tosoh Group, a Japanese chemical and specialty products group, founded 1935, which comprises over 100 companies worldwide and a workforce of more than 14,000 people.
Tosoh Bioscience führt ein neues Hydroxyapatit-Medium für die Aufreinigung von Biomolekülen ein. Ca⁺⁺Pure-HA bietet außergewöhnliche Trenneigenschaften und eine beispiellose Selektivität und Auflösung für die Reinigung verschiedener Biomolekülklassen. Ca++Pure-HA unterstützt die Bestrebungen der pharmazeutischen Industrie, die Herstellungskosten von biologischen Arzneimitteln zu senken.
